Treatment Response Evaluation in Gastrointestinal Stromal Tumor (GIST) Patients
1 other identifier
observational
40
1 country
1
Brief Summary
The purpose of this study is to compare sensitivity, specificity and accuracy of PET, DW MRI and CT separately and combined for the evaluation of treatment response and progression-free survival in patients with GIST.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Feb 2011
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 12, 2011
CompletedFirst Posted
Study publicly available on registry
January 13, 2011
CompletedStudy Start
First participant enrolled
February 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
June 21, 2017
CompletedJune 22, 2017
June 1, 2017
6.3 years
January 12, 2011
June 21, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Radiologic-pathologic correlation
2 years
Eligibility Criteria
GIST patients suitable for medical treatment with targeted therapies.
You may qualify if:
- Metastatic GIST patients suitable for TKI treatment
- GIST patients pursuing preoperative neoadjuvant TKI treatment
You may not qualify if:
- Patients with contraindications to MRI and/or TKI treatment. For patients with renal failure, CT without intravenous contrast will be performed according to clinical practice.
- Patients who do not sign the consent paper for any reason or do not accept the study premises or patients who wish to withdraw for any reason during the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Oslo University Hosptal
Oslo, 0424, Norway
Related Publications (1)
Revheim ME, Hole KH, Bruland OS, Reitan E, Bjerkehagen B, Julsrud L, Seierstad T. Multimodal functional imaging for early response assessment in GIST patients treated with imatinib. Acta Oncol. 2014 Jan;53(1):143-8. doi: 10.3109/0284186X.2013.798428. Epub 2013 May 28. No abstract available.
PMID: 23710697DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mona-Elisabeth Revheim, MD
Oslo University Hospital, Dept of Nuclear Medicine
- STUDY CHAIR
Therese Seierstad, PhD
Oslo University Hospital, Institute for Cancer Research
- PRINCIPAL INVESTIGATOR
Øyvind S Bruland, Prof., MD
Oslo University Hospital, Dept of Oncology, The Norwegian Radium Hospital
- PRINCIPAL INVESTIGATOR
Knut Håkon Hole, MD
Oslo University Hospital, Department of Diagnostic Radiology
- PRINCIPAL INVESTIGATOR
Lars Julsrud, MD
Oslo University Hospital, Department of Diagnostic Radiology
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Nuclear Medicine Phycisian
Study Record Dates
First Submitted
January 12, 2011
First Posted
January 13, 2011
Study Start
February 1, 2011
Primary Completion
June 1, 2017
Study Completion
June 21, 2017
Last Updated
June 22, 2017
Record last verified: 2017-06